风险提示：1）行业竞争加剧风险。2）政策监管趋严风险。3）宏观经济不及预期风险。 周专题：从锦欣康养上市申请看我国康养行业发展 锦欣康养为中国机构养老服务市场领导者，战略聚焦高龄（80 岁以上）及有迫切养老需求（如行动 不便、慢性病、认知障碍）的老年人。截至 2025 年 9 月 30 日，公司管理及运营 38 家养老设施， 主要存在于川渝区域，因而川渝地区贡献 71.8%的收入。通过内生+并购形式推动公司收入持续增 长，2024 年公司收入为 6.05 亿元，同比增长 23.8%， 2025Q1-3 同比增速仍保持在 22.0%；公司 2023-2024 年毛利率（21.7%-24.5%区间）、净利率（6.0-8.0%区间）整体保持稳定；公司增长并 非来自高营销投入，2025Q1-3 销售费用率仅 0.81%。 我国人口老龄化及支付能力提升催动我国康养需求增长。消费水平提升下，老年人需求从 "基本生 活保障" 向追求有尊严、自主选择及掌控的高品质老年生活转变，加速了高端养老服务的发展。医 疗养老结合服务满足了老年人对医疗资源的需求特点，在资金以及需求上更具韧性，因此近年增长 更为稳健。此外，康养行业现存问题 ...

医药周报 20260301 从锦欣康养上市申请看我国康养行业发展 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从锦欣康养上市申请看我国康养行业发展 锦欣康养为中国机构养老服务市场领导者，战略聚焦高龄（80 岁以上）及有迫切养老需求（如行动 不便、慢性病、认知障碍）的老年人。截至 2025 年 9 月 30 日，公司管理及运营 38 家养老设施， 主要存在于川渝区域，因而川渝地区贡献 71.8%的收入。通过内生+并购形式推动公司收入持续增 长，2024 年公司收入为 6.05 亿元，同比增长 23.8%， 2025Q1-3 同比增速仍保持在 22.0%；公司 2023-2024 年毛利率（21.7%-24.5%区间）、净利率（6.0-8.0%区间）整体保持稳定；公司增长并 非来自高营销投入，2025Q1-3 销售费用率仅 0.81%。 我国人口老龄化及支付能力提升催动我国康养需求增长。消费水平提升下，老年人需求从 "基本生 活保障" 向追求有尊严、自主选择及掌控的高品质老年生活转变，加速了高端养老服务的发展。医 疗养老结合服务满足了老年人对医疗资源的需求特点，在资金以及需求上更具韧性，因 ...

格隆汇2月24日丨科济药业-B(02171.HK)公告，董事会兹通告谨定于2026年3月6日(星期五)举行董事会 会议，以考虑及通过集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱「本集 團」）董事會（「董事會」）茲通告謹定於2026年3月6日（星期五）舉行董事會會議， 以考慮及通過本集團截至2025年12月31日止年度的全年業績，以及處理其他事 項。 承董事會命 科濟藥業控股有限公司 董事長 李宗海博士 香港，2026年2月24日 於本公告日期，本公司董事會包括執行董事李宗海博士、王華茂博士及蔣華博 士；非執行董事郭華清先生及謝榕剛先生；獨立非執行董事顏光美博士、趙向可 女士及周文博士。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 董事會會議召開日期 ...

Market Performance - During the Chinese New Year holiday from February 15 to February 23, the Hong Kong stock market experienced a volatile performance, with the Hang Seng Index rising by 1.94% and the Hang Seng China Enterprises Index increasing by 1.82% [1][3] - On February 20, the first trading day of the Year of the Horse, the market showed weakness overall, but hard technology stocks surged, with over 40 leading stocks with a market capitalization greater than HKD 3 billion showing significant gains [3][4] Technology Sector Highlights - Leading the gains, Zhiyu Technology saw a remarkable increase of 42.72%, closing at HKD 725, with a market capitalization surpassing HKD 323.2 billion [4] - Other notable performers included Tian Shu Zhi Xin, which rose by 34.40%, and Yue Jiang, which increased by 30.77%, indicating a strong shift of capital from comprehensive platforms to niche technology stocks [4][19] Catalysts for Growth - The 2026 Spring Festival Gala was a significant catalyst for the technology market, showcasing advancements in robotics and AI, which ignited consumer interest and market enthusiasm [6][9] - The performance of AI technologies during the gala, including the application of the Seedance 2.0 model, demonstrated the deep integration of AI in mainstream applications [9][11] AI and Semiconductor Developments - Zhiyu Technology's stock surge was supported by the release of its flagship model GLM-5, which outperformed competitors in benchmark tests and opened new market opportunities [11][12] - The semiconductor sector is experiencing a "super cycle," with memory chip prices soaring by 80%-90% in Q1 2026, driven by unprecedented demand from AI applications [18][19] Robotics and New Energy - The robotics industry is witnessing rapid industrialization, with companies like Yujing and Songyan Power showing significant stock price increases due to advancements in humanoid robots and electric vehicle exports [21][22] - The new energy sector, particularly hydrogen energy, is entering a high-growth phase, supported by accelerated infrastructure development and increasing demand for clean energy solutions [25]

Core Viewpoint - The Hang Seng Index will undergo changes, increasing its constituent stocks from 88 to 90, with the inclusion of Ningde Times, Luoyang Molybdenum, and Laopu Gold, while Zhongsheng Holdings will be removed. This change will take effect on March 9, 2026 [1][6]. Group 1: Index Changes - The Hang Seng Index will increase its constituent stocks from 88 to 90, adding Ningde Times (03750.HK), Luoyang Molybdenum (03993.HK), and Laopu Gold (06181.HK), while removing Zhongsheng Holdings [1][6]. - The Hang Seng China Enterprises Index will maintain 50 stocks, adding Beike (02423.HK) and Horizon Robotics (09660.HK), while removing China Resources Beer (00291.HK) and Mengniu Dairy (02319.HK) [2][7]. - The Hang Seng Composite Index will increase from 507 to 532 stocks, removing 28 stocks and adding 53 new ones, including East Asia Bank, Rusal, and JD Industrial [2][7]. Group 2: Market Outlook - Despite recent adjustments in the Hong Kong stock market, particularly with major stocks like Tencent, Meituan, and Alibaba experiencing significant declines, institutional and investor expectations for the market remain high, with continued investments in related ETFs [1][6]. - Recent liquidity shocks have affected the technology sector, but the fundamental outlook remains unchanged, suggesting a potential rebound as the market stabilizes [3][8]. - The consumer sector in Hong Kong is expected to benefit from improving economic conditions, with traditional industries undergoing transformation and leading to potential valuation recovery [5][9].

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Kintor Pharmaceutical-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostic Technology, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for this project will not exceed RMB 370 million, aimed at constructing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Core Viewpoint - The Hang Seng Index will undergo changes with the number of constituent stocks increasing from 88 to 90, including the addition of Ningde Times, Luoyang Molybdenum, and Laopu Gold, while Zhongsheng Holdings will be removed. This change will take effect on March 9, 2026 [1][2]. Group 1: Hang Seng Index Changes - The Hang Seng Index Company announced the quarterly review results on February 13, 2026, with changes effective after market close on March 6, 2026 [1]. - The total assets under management for passive products tracking the Hang Seng Index series is approximately $117.7 billion, which is beneficial for newly added constituents as they will attract passive fund inflows [1]. Group 2: Other Index Changes - The Hang Seng China Enterprises Index will maintain 50 constituent stocks, with Beike and Horizon Robotics added, while China Resources Beer and Mengniu Dairy will be removed [2]. - The Hang Seng Composite Index will increase from 507 to 532 constituent stocks, with 53 stocks added and 28 stocks removed, including notable additions like East Asia Bank and JD Industrial [2]. Group 3: Market Outlook - Recent weakness in the Hang Seng Technology Index is attributed to a liquidity shock, but the fundamental outlook remains unchanged, suggesting a "buy the dip" strategy may be effective [3]. - The current support from southbound funds is expected to stabilize valuations in the Hong Kong market, despite ongoing uncertainties regarding U.S. Federal Reserve policies [3][4]. - The market may experience volatility in the short term, with a focus on sectors such as technology, non-bank financials, and dividend-paying stocks [4].

Core Viewpoint - Kintor Pharmaceutical (02171.HK) has signed a strategic cooperation agreement with Shanghai Jinkong Enterprise Development to invest up to 370 million yuan in building a CAR-T cell therapy product commercialization production base in Shanghai's Jinshan District, aligning with the commercialization process of multiple CAR-T products [1][2]. Group 1: Investment and Production Base - The total investment for the new CAR-T drug production base is capped at 370 million yuan, with the construction managed by Shanghai Jinkong [1]. - The investment will be executed through a phased payment model, allowing Kintor to retain cash flow for core R&D and new drug promotion [3]. - The construction is expected to take 14 months, with Kintor making quarterly service fee payments during the initial years [3]. Group 2: Product Development and Market Potential - Kintor's CAR-T product, Shurui Kiorunai, is currently under review for market approval and is the first entity-targeting CAR-T product to submit a New Drug Application in China [2]. - The product targets Claudin18.2 positive advanced gastric/esophageal junction adenocarcinoma, with clinical trial results showing superior efficacy compared to existing therapies [2]. - The market for gastric cancer treatment is significant, with 358,700 new cases and 260,400 deaths reported in 2022 in China, indicating a high demand for effective therapies [2]. Group 3: Financial Performance - Kintor expects a significant reduction in net losses, projecting a loss of no more than 120 million yuan for the reporting period, down from 798 million yuan in the previous year [4]. - The reduction in losses is attributed to increased commercialization revenue from the existing product, Zewokiorunai, and decreased R&D expenditures for both Zewokiorunai and Shurui Kiorunai [4]. - As of June 30, 2025, Kintor reported cash and bank balances of approximately 1.261 billion yuan, indicating sufficient cash flow until 2028 without considering future inflows [3].

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]